ESC Symposium Highlights VIVO's 90% Accuracy in Addressing Complex VT

Catheter Precision, Inc. (NYSE American: VTAK) recently presented interim results demonstrating the efficacy of VIVO at the European Society of Cardiology Symposium. The findings, from an ongoing study at Warwick Medical School, showed VIVO's 90% accuracy in localizing the site of origin of ventricular tachycardia (VT) in patients with structural heart disease.

The study covered twenty patients with an average ejection fraction of 35.5%. It compared VIVO's non-invasive mapping against Abbott Advisor HD Grid multipolar catheter. Results revealed that VIVO particularly matched accurately in areas of myocardial scar tissue. At a seven-month follow-up, procedural success was noted in 90% of the cases.

David Jenkins, CEO of Catheter Precision, emphasized the significance of these results for patients with serious heart conditions. He expressed optimism for further enrollments and eventual conclusions expected to expand VIVO's indications in the US.